A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of Montelukast in patients with mild to moderate Alzheimer's Disease

Trial Profile

A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of a new buccal film of Montelukast in patients with mild to moderate Alzheimer's Disease

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 09 Nov 2017 According to an IntelGenx Corp. media release, the company has submitted a clinical trial application (CTA) tot he Health Canada for approval to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top